#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


1-1	0-10	Disruption	_
1-2	11-13	of	_
1-3	14-21	frontal	_
1-4	22-26	lobe	_
1-5	27-33	neural	_
1-6	34-43	synchrony	_
1-7	44-50	during	_
1-8	51-60	cognitive	_
1-9	61-68	control	_
1-10	69-71	by	_
1-11	72-79	alcohol	_
1-12	80-92	intoxication	_
1-13	93-101	Decision	_
1-14	102-108	making	_
1-15	109-115	relies	_
1-16	116-118	on	_
1-17	119-126	dynamic	_
1-18	127-139	interactions	_
1-19	140-142	of	_
1-20	143-154	distributed	_
1-21	155-156	,	_
1-22	157-166	primarily	_
1-23	167-174	frontal	_
1-24	175-180	brain	_
1-25	181-188	regions	_
1-26	189-190	.	_

2-1	191-200	Extensive	_
2-2	201-209	evidence	_
2-3	210-214	from	_
2-4	215-225	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
2-5	226-234	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
2-6	235-244	resonance	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
2-7	245-252	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
2-8	253-254	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
2-9	255-259	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
2-10	260-261	)	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
2-11	262-269	studies	_
2-12	270-279	indicates	_
2-13	280-284	that	_
2-14	285-288	the	_
2-15	289-297	anterior	_
2-16	298-307	cingulate	_
2-17	308-309	(	_
2-18	310-313	ACC	_
2-19	314-315	)	_
2-20	316-319	and	_
2-21	320-323	the	_
2-22	324-331	lateral	_
2-23	332-342	prefrontal	_
2-24	343-351	cortices	_
2-25	352-353	(	_
2-26	354-360	latPFC	_
2-27	361-362	)	_
2-28	363-366	are	_
2-29	367-376	essential	_
2-30	377-382	nodes	_
2-31	383-393	subserving	_
2-32	394-403	cognitive	_
2-33	404-411	control	_
2-34	412-413	.	_

3-1	414-421	However	_
3-2	422-423	,	_
3-3	424-431	because	_
3-4	432-434	of	_
3-5	435-438	its	_
3-6	439-446	limited	_
3-7	447-455	temporal	_
3-8	456-466	resolution	_
3-9	467-468	,	_
3-10	469-473	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-11	474-477	can	_
3-12	478-481	not	_
3-13	482-492	accurately	_
3-14	493-500	reflect	_
3-15	501-504	the	_
3-16	505-511	timing	_
3-17	512-515	and	_
3-18	516-522	nature	_
3-19	523-525	of	_
3-20	526-531	their	_
3-21	532-540	presumed	_
3-22	541-550	interplay	_
3-23	551-552	.	_

4-1	553-556	The	_
4-2	557-564	present	_
4-3	565-570	study	_
4-4	571-579	combines	_
4-5	580-591	distributed	_
4-6	592-598	source	_
4-7	599-607	modeling	_
4-8	608-610	of	_
4-9	611-614	the	_
4-10	615-625	temporally	_
4-11	626-633	precise	_
4-12	634-637	MEG	_
4-13	638-644	signal	_
4-14	645-649	with	_
4-15	650-660	structural	_
4-16	661-664	MRI	_
4-17	665-667	in	_
4-18	668-671	the	_
4-19	672-676	form	_
4-20	677-679	of	_
4-21	680-681	“	_
4-22	682-687	brain	_
4-23	688-694	movies	_
4-24	695-696	”	_
4-25	697-699	to	_
4-26	700-708	estimate	_
4-27	709-710	:	_
4-28	711-712	1	_
4-29	713-714	)	_
4-30	715-718	the	_
4-31	719-727	cortical	_
4-32	728-733	areas	_
4-33	734-742	involved	_
4-34	743-745	in	_
4-35	746-755	cognitive	_
4-36	756-763	control	_
4-37	764-765	(	_
4-38	766-767	“	_
4-39	768-773	where	_
4-40	774-775	”	_
4-41	776-777	)	_
4-42	778-779	,	_
4-43	780-781	2	_
4-44	782-783	)	_
4-45	784-786	to	_
4-46	787-799	characterize	_
4-47	800-805	their	_
4-48	806-814	temporal	_
4-49	815-823	sequence	_
4-50	824-825	(	_
4-51	826-827	“	_
4-52	828-832	when	_
4-53	833-834	”	_
4-54	835-836	)	_
4-55	837-838	,	_
4-56	839-842	and	_
4-57	843-844	3	_
4-58	845-846	)	_
4-59	847-849	to	_
4-60	850-858	quantify	_
4-61	859-862	the	_
4-62	863-874	oscillatory	_
4-63	875-883	dynamics	_
4-64	884-886	of	_
4-65	887-892	their	_
4-66	893-899	neural	_
4-67	900-912	interactions	_
4-68	913-915	in	_
4-69	916-920	real	_
4-70	921-925	time	_
4-71	926-927	.	_

5-1	928-934	Stroop	_
5-2	935-947	interference	_
5-3	948-951	was	_
5-4	952-962	associated	_
5-5	963-967	with	_
5-6	968-975	greater	_
5-7	976-989	event-related	_
5-8	990-995	theta	_
5-9	996-997	(	_
5-10	998-1001	4–7	_
5-11	1002-1004	Hz	_
5-12	1005-1006	)	_
5-13	1007-1012	power	_
5-14	1013-1015	in	_
5-15	1016-1019	the	_
5-16	1020-1023	ACC	_
5-17	1024-1030	during	_
5-18	1031-1039	conflict	_
5-19	1040-1049	detection	_
5-20	1050-1058	followed	_
5-21	1059-1061	by	_
5-22	1062-1071	sustained	_
5-23	1072-1083	sensitivity	_
5-24	1084-1086	to	_
5-25	1087-1096	cognitive	_
5-26	1097-1104	demands	_
5-27	1105-1107	in	_
5-28	1108-1111	the	_
5-29	1112-1115	ACC	_
5-30	1116-1119	and	_
5-31	1120-1126	latPFC	_
5-32	1127-1133	during	_
5-33	1134-1145	integration	_
5-34	1146-1149	and	_
5-35	1150-1158	response	_
5-36	1159-1170	preparation	_
5-37	1171-1172	.	_

6-1	1173-1174	A	_
6-2	1175-1188	phase-locking	_
6-3	1189-1197	analysis	_
6-4	1198-1206	revealed	_
6-5	1207-1221	co-oscillatory	_
6-6	1222-1234	interactions	_
6-7	1235-1242	between	_
6-8	1243-1248	these	_
6-9	1249-1254	areas	_
6-10	1255-1265	indicating	_
6-11	1266-1271	their	_
6-12	1272-1281	increased	_
6-13	1282-1288	neural	_
6-14	1289-1298	synchrony	_
6-15	1299-1301	in	_
6-16	1302-1307	theta	_
6-17	1308-1312	band	_
6-18	1313-1319	during	_
6-19	1320-1337	conflict-inducing	_
6-20	1338-1349	incongruous	_
6-21	1350-1356	trials	_
6-22	1357-1358	.	_

7-1	1359-1364	These	_
7-2	1365-1372	results	_
7-3	1373-1380	confirm	_
7-4	1381-1385	that	_
7-5	1386-1391	theta	_
7-6	1392-1404	oscillations	_
7-7	1405-1408	are	_
7-8	1409-1420	fundamental	_
7-9	1421-1423	to	_
7-10	1424-1434	long-range	_
7-11	1435-1450	synchronization	_
7-12	1451-1457	needed	_
7-13	1458-1461	for	_
7-14	1462-1473	integrating	_
7-15	1474-1482	top-down	_
7-16	1483-1493	influences	_
7-17	1494-1500	during	_
7-18	1501-1510	cognitive	_
7-19	1511-1518	control	_
7-20	1519-1520	.	_

8-1	1521-1524	MEG	_
8-2	1525-1533	reflects	_
8-3	1534-1540	neural	_
8-4	1541-1549	activity	_
8-5	1550-1558	directly	_
8-6	1559-1564	which	_
8-7	1565-1570	makes	_
8-8	1571-1573	it	_
8-9	1574-1582	suitable	_
8-10	1583-1586	for	_
8-11	1587-1602	pharmacological	_
8-12	1603-1616	manipulations	_
8-13	1617-1619	in	_
8-14	1620-1628	contrast	_
8-15	1629-1631	to	_
8-16	1632-1636	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
8-17	1637-1642	which	_
8-18	1643-1645	is	_
8-19	1646-1655	sensitive	_
8-20	1656-1658	to	_
8-21	1659-1669	vasoactive	_
8-22	1670-1679	confounds	_
8-23	1680-1681	.	_

9-1	1682-1684	In	_
9-2	1685-1688	the	_
9-3	1689-1696	present	_
9-4	1697-1702	study	_
9-5	1703-1704	,	_
9-6	1705-1712	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
9-7	1713-1719	social	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
9-8	1720-1728	drinkers	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
9-9	1729-1733	were	_
9-10	1734-1739	given	_
9-11	1740-1741	a	_
9-12	1742-1750	moderate	_
9-13	1751-1758	alcohol	_
9-14	1759-1763	dose	_
9-15	1764-1767	and	_
9-16	1768-1775	placebo	_
9-17	1776-1778	in	_
9-18	1779-1780	a	_
9-19	1781-1795	within-subject	_
9-20	1796-1802	design	_
9-21	1803-1804	.	_

10-1	1805-1810	Acute	_
10-2	1811-1823	intoxication	_
10-3	1824-1834	attenuated	_
10-4	1835-1840	theta	_
10-5	1841-1846	power	_
10-6	1847-1849	to	_
10-7	1850-1856	Stroop	_
10-8	1857-1865	conflict	_
10-9	1866-1869	and	_
10-10	1870-1882	dysregulated	_
10-11	1883-1898	co-oscillations	_
10-12	1899-1906	between	_
10-13	1907-1910	the	_
10-14	1911-1914	ACC	_
10-15	1915-1918	and	_
10-16	1919-1925	latPFC	_
10-17	1926-1936	confirming	_
10-18	1937-1941	that	_
10-19	1942-1949	alcohol	_
10-20	1950-1952	is	_
10-21	1953-1964	detrimental	_
10-22	1965-1967	to	_
10-23	1968-1974	neural	_
10-24	1975-1984	synchrony	_
10-25	1985-1995	subserving	_
10-26	1996-2005	cognitive	_
10-27	2006-2013	control	_
10-28	2014-2015	.	_

11-1	2016-2018	It	_
11-2	2019-2029	interferes	_
11-3	2030-2034	with	_
11-4	2035-2048	goal-directed	_
11-5	2049-2057	behavior	_
11-6	2058-2063	which	_
11-7	2064-2067	may	_
11-8	2068-2074	result	_
11-9	2075-2077	in	_
11-10	2078-2087	deficient	_
11-11	2088-2100	self-control	_
11-12	2101-2102	,	_
11-13	2103-2115	contributing	_
11-14	2116-2118	to	_
11-15	2119-2129	compulsive	_
11-16	2130-2138	drinking	_
11-17	2139-2140	.	_

12-1	2141-2143	In	_
12-2	2144-2147	sum	_
12-3	2148-2149	,	_
12-4	2150-2154	this	_
12-5	2155-2161	method	_
12-6	2162-2165	can	_
12-7	2166-2173	provide	_
12-8	2174-2181	insight	_
12-9	2182-2186	into	_
12-10	2187-2196	real-time	_
12-11	2197-2209	interactions	_
12-12	2210-2216	during	_
12-13	2217-2226	cognitive	_
12-14	2227-2237	processing	_
12-15	2238-2241	and	_
12-16	2242-2245	can	_
12-17	2246-2258	characterize	_
12-18	2259-2262	the	_
12-19	2263-2272	selective	_
12-20	2273-2284	sensitivity	_
12-21	2285-2287	to	_
12-22	2288-2303	pharmacological	_
12-23	2304-2313	challenge	_
12-24	2314-2320	across	_
12-25	2321-2329	relevant	_
12-26	2330-2336	neural	_
12-27	2337-2345	networks	_
12-28	2346-2347	.	_

13-1	2348-2353	SHORT	_
13-2	2354-2362	ABSTRACT	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent
13-3	2363-2364	:	_
13-4	2365-2369	This	_
13-5	2370-2380	experiment	_
13-6	2381-2385	uses	_
13-7	2386-2388	an	_
13-8	2389-2413	anatomically-constrained	_
13-9	2414-2436	magnetoencephalography	http://maven.renci.org/NeuroBridge/neurobridge#Magnetoencephalography
13-10	2437-2438	(	http://maven.renci.org/NeuroBridge/neurobridge#Magnetoencephalography
13-11	2439-2443	aMEG	http://maven.renci.org/NeuroBridge/neurobridge#Magnetoencephalography
13-12	2444-2445	)	http://maven.renci.org/NeuroBridge/neurobridge#Magnetoencephalography
13-13	2446-2452	method	_
13-14	2453-2455	to	_
13-15	2456-2463	examine	_
13-16	2464-2469	brain	_
13-17	2470-2481	oscillatory	_
13-18	2482-2490	dynamics	_
13-19	2491-2494	and	_
13-20	2495-2505	long-range	_
13-21	2506-2516	functional	_
13-22	2517-2526	synchrony	_
13-23	2527-2533	during	_
13-24	2534-2544	engagement	_
13-25	2545-2547	of	_
13-26	2548-2557	cognitive	_
13-27	2558-2565	control	_
13-28	2566-2568	as	_
13-29	2569-2570	a	_
13-30	2571-2579	function	_
13-31	2580-2582	of	_
13-32	2583-2588	acute	_
13-33	2589-2596	alcohol	_
13-34	2597-2609	intoxication	_
13-35	2610-2611	.	_

